Search

Your search keyword '"Minoia, C"' showing total 20 results
Start Over Author "Minoia, C" Publisher wiley
20 results on '"Minoia, C"'

2. Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs—Data from International Prospective T‐Cell Project 2.0

Author

Skrypets, T., primary, Chauvie, S., additional, Manni, M., additional, Fallanca, F., additional, Racca, M., additional, Hitz, F., additional, Advani, R., additional, Ramos, C. D., additional, Miranda, E., additional, Tomuleasa, C., additional, Minoia, C., additional, Marino, D., additional, Noyan‐Atalay, F., additional, Stepanishyna, Y., additional, De Maggi, A., additional, Marcheselli, L., additional, Chang, C., additional, Federico, M., additional, and Luminari, S., additional

Published
2023
Full Text
View/download PDF

3. FERTILITY PRESERVATION IN ADULT LYMPHOMA PATIENTS: A CONSENSUS‐BASED POSITION PAPER BY THE FONDAZIONE ITALIANA LINFOMI (FIL) & SOCIETà ITALIANA DELLA RIPRODUZIONE UMANA (SIRU)

Author

Minoia, C., primary, Viviani, S., additional, Silvestris, E., additional, Palini, S., additional, Parissone, F., additional, De Palma, G., additional, Fedina, A., additional, Cormio, G., additional, Guarini, A., additional, Gini, G., additional, Montano, L., additional, Merli, F., additional, and Peccatori, F. A., additional

Published
2023
Full Text
View/download PDF

4. LATE TOXICITIES AND LONG‐TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI

Author

Minoia, C., primary, Gerardi, C., additional, Allocati, E., additional, De Sanctis, V., additional, Franceschetti, S., additional, Viviani, S., additional, Annunziata, M. A., additional, Bari, A., additional, Skrypets, T., additional, Oliva, S., additional, Puzzovivo, A., additional, Di Molfetta, S., additional, Caccavari, V., additional, Di Russo, A., additional, Loseto, G., additional, Daniele, A., additional, Nassi, L., additional, Gini, G., additional, and Guarini, A., additional

Published
2021
Full Text
View/download PDF

5. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0

Author

Federico, M, primary, Chiattone, C. S, additional, Prince, H. M, additional, Pavlovsky, A, additional, Manni, M, additional, Civallero, M, additional, Skrypets, T, additional, De Souza, C. A, additional, Hawkes, E. A, additional, Fiad, L, additional, Lymboussakis, A, additional, Tomuleasa, C, additional, Nair, R, additional, Pereira, J, additional, Pereyra, P, additional, Minoia, C, additional, Kryachok, I, additional, de Castro, N. S, additional, Advani, R. H, additional, and Luminari, S, additional

Published
2021
Full Text
View/download PDF

6. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE

Author

Federico, M., primary, Caballero, D., additional, Marcheselli, L., additional, Tarantino, V., additional, Sarkozy, C., additional, Lopez Guillermo, A., additional, Wondergem, M., additional, Kimby, E., additional, Rusconi, C., additional, Zucca, E., additional, Montoto, S., additional, da Silva, M.G., additional, Aurer, I., additional, Paszkiewicz-Kozik, E., additional, Cartron, G., additional, Morschhauser, F., additional, Alcoceba, M., additional, Chamuleau, M., additional, Lockmer, S., additional, Minoia, C., additional, Issa, D., additional, Alonso, S., additional, Conte, L., additional, Salles, G., additional, and Coiffier, B., additional

Published
2017
Full Text
View/download PDF

7. Heavy metals in human amniotic fluid: a pilot study

Author

Caserta, D., primary, Mantovani, A., additional, Ciardo, F., additional, Fazi, A., additional, Baldi, M., additional, Sessa, M. T., additional, la Rocca, C., additional, Ronchi, A., additional, Moscarini, M., additional, and Minoia, C., additional

Published
2011
Full Text
View/download PDF

19. Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.

Author

Argnani L, Broccoli A, Pellegrini C, Fabbri A, Puccini B, Bruna R, Tisi MC, Masia F, Flenghi L, Nizzoli ME, Musso M, Salerno M, Scalzulli PR, Dessi' D, Ferrarini I, Pennese E, Lucchini E, Rossi FG, Minoia C, Gherlinzoni F, Musto P, Patti C, Stefoni V, and Zinzani PL

Abstract

After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access through a Named Patient Program. A multicentric observational retrospective study was conducted focusing on the effectiveness and safety of PolaBR in everyday clinical practice. Fifty-five patients were enrolled. There were 26 females (47.3%), 32 patients were primary refractory and 45 (81.8%) resulted refractory to their last therapy. The decision to add or not bendamustine was at physician's discretion. Thirty-six patients underwent PolaBR, and 19 PolaR. The 2 groups did not differ in most of baseline characteristics. The final overall response rate was 32.7% (18.2% complete response rate), with a best response rate of 49.1%. Median disease-free survival was reached at 12 months, median progression-free survival at 4.9 months and median overall survival at 9 months, respectively. Overall, 88 adverse events (AEs) were registered during treatment in 31 patients, 22 of grade ≥3. Eight cases of neuropathy occurred, all of grades 1-2 and all related to polatuzumab. The two groups of treatment did not differ for effectiveness endpoints but presented statistically significant difference in AEs occurrence, especially in hematological AEs, in AEs of grade equal or greater than 3 and in incidence of neuropathy. Our data add useful information on the effectiveness of Pola(B)R in the setting of heavily pretreated DLBCL and may also suggest a better tolerability in absence of bendamustine without compromise of efficacy., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.)

Published
2022
Full Text
View/download PDF

20. Allergological and toxicological aspects in a multiple chemical sensitivity cohort.

Author

Pigatto PD, Minoia C, Ronchi A, Brambilla L, Ferrucci SM, Spadari F, Passoni M, Somalvico F, Bombeccari GP, and Guzzi G

Subjects
Adult, Body Mass Index, Cohort Studies, Dental Amalgam adverse effects, Diet, Dietary Supplements, Female, Hair metabolism, Hormones metabolism, Humans, Hypersensitivity blood, Hypersensitivity epidemiology, Hypersensitivity urine, Italy epidemiology, Male, Marital Status, Mercury blood, Mercury urine, Multiple Chemical Sensitivity blood, Multiple Chemical Sensitivity epidemiology, Multiple Chemical Sensitivity urine, Prevalence, Risk Factors, Rural Population, Saliva metabolism, Smoking adverse effects, Urban Population, Hypersensitivity complications, Metals adverse effects, Multiple Chemical Sensitivity complications
Abstract

Background: Multiple chemical sensitivity (MCS) is a chronic condition characterized by an exaggerated response to toxicants. We ascertained the prevalence of allergy to metals and toxicological aspects in MCS patients., Methods: We conducted a retrospective review of medical records of 41 patients with MCS. We performed patch testing (n = 21) for dental series and did lymphocyte transformation test (n = 18) for metals. We measured mercury in samples of blood (n = 19), urine (n = 19), saliva (n = 20), and scalp hair (n = 17) to investigate the association between mercury levels and cases of MCS., Results: The prevalence of metal immune hypersensitivity in a subset of 26 patients was 92.3 percent. Elevations of mercury occurred in 81.2 percent (26 of 32). The mean (±SD) in blood concentrations of mercury was 7.6 ± 13.6 μg/L; mean in urine was 1.9 ± 2.5 μg/L; mean in scalp hair was 2.2 ± 2.5 μg/g; mean in saliva was 38.1 ± 52.1 μg/L. Subgroup analyses showed that elevation of mercury levels in biological matrices were associated with mercury amalgams in patients with MCS (22 patients), compared with controls (8 patients) (odds ratio 11 : 95 percent confidence interval 1.5 to 81.6; P = 0.023)., Conclusions: Our data show an increased prevalence of metal allergy and elevation of mercury levels in bioindicators among patients with MCS.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results